FDA approves oral solution Cuvposa for chronic drooling in children

07/29/2010 | Modern Medicine

The FDA approved Shionogi Pharma's Cuvposa, a flavored liquid form of glycopyrrolate, for the treatment of chronic drooling in patients ages 3 to 16 with neuromuscular disorders. Glycopyrrolate has long been approved for patients with peptic ulcers and to reduce salivation among those under anesthesia.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC